Vaxcyte, Inc. (PCVX)
NASDAQ: PCVX · Real-Time Price · USD
88.39
+2.43 (2.83%)
At close: Nov 21, 2024, 4:00 PM
89.37
+0.98 (1.11%)
After-hours: Nov 21, 2024, 4:47 PM EST
Vaxcyte Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Cost of Revenue | 75 | 75 | 23 | - | - | - | |
| Gross Profit | -75 | -75 | -23 | - | - | - | |
| Selling, General & Admin | 81.87 | 60.7 | 39.81 | 25.26 | 16.02 | 8.55 | |
| Research & Development | 447.18 | 332.34 | 169.45 | 78.41 | 73.56 | 45.61 | |
| Operating Expenses | 529.05 | 393.04 | 209.26 | 103.67 | 89.58 | 54.15 | |
| Operating Income | -604.05 | -468.04 | -232.26 | -103.67 | -89.58 | -54.15 | |
| Interest Expense | - | - | -0 | -0.01 | -0.01 | -0.04 | |
| Interest & Investment Income | 91.1 | 62.91 | 8.36 | 0.34 | 0.24 | 0.63 | |
| Currency Exchange Gain (Loss) | 4.43 | -1.9 | -1.47 | 1.67 | -2.35 | -0.14 | |
| Other Non Operating Income (Expenses) | 0.82 | 4.77 | 1.93 | 1.59 | 2.48 | 0.24 | |
| EBT Excluding Unusual Items | -507.7 | -402.27 | -223.44 | -100.08 | -89.22 | -53.46 | |
| Gain (Loss) on Sale of Investments | 0.05 | - | - | 0 | - | - | |
| Gain (Loss) on Sale of Assets | - | - | -0.04 | - | - | - | |
| Other Unusual Items | - | - | - | - | - | 3.19 | |
| Pretax Income | -507.65 | -402.27 | -223.49 | -100.08 | -89.22 | -50.27 | |
| Net Income | -507.65 | -402.27 | -223.49 | -100.08 | -89.22 | -50.27 | |
| Net Income to Common | -507.65 | -402.27 | -223.49 | -100.08 | -89.22 | -50.27 | |
| Shares Outstanding (Basic) | 114 | 97 | 65 | 52 | 30 | 4 | |
| Shares Outstanding (Diluted) | 114 | 97 | 65 | 52 | 30 | 4 | |
| Shares Change (YoY) | 24.70% | 49.75% | 24.95% | 75.73% | 678.53% | 4.55% | |
| EPS (Basic) | -4.46 | -4.14 | -3.44 | -1.93 | -3.02 | -13.25 | |
| EPS (Diluted) | -4.46 | -4.14 | -3.44 | -1.93 | -3.02 | -13.25 | |
| Free Cash Flow | -616.24 | -364.67 | -176.45 | -127.95 | -47.78 | -48.34 | |
| Free Cash Flow Per Share | -5.41 | -3.75 | -2.72 | -2.46 | -1.62 | -12.74 | |
| EBITDA | -599.03 | -464.89 | -229.68 | -101.87 | -88.18 | -52.92 | |
| D&A For EBITDA | 5.03 | 3.16 | 2.58 | 1.8 | 1.41 | 1.23 | |
| EBIT | -604.05 | -468.04 | -232.26 | -103.67 | -89.58 | -54.15 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.